Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8722706 | HPB | 2018 | 10 Pages |
Abstract
The liver-first approach is feasible with acceptable perioperative morbidity and mortality rates. Despite the considerable overall-survival-benefit, recurrence rates remain high. Future research should focus on providing selection tools to enable the optimal treatment sequence for each patient with synchronous CRLM.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Mechteld C. de Jong, Rianne C.J. Beckers, Victor van Woerden, Julie M.L. Sijmons, Marc H.A. Bemelmans, Ronald M. van Dam, Cornelis H.C. Dejong,